International Circulation: International Circulation is honored to speak to Professor Suzanne Oparil on the occasion of WHC2009 in Beijing and this Chinese guidelines preparatory meeting.
We know the ESH/ESC and the Japanese JSH just updated their guidelines for hypertension management， and China and the United States are also in the process of updating their hypertension guidelines. From your perspective， why are organizations updating their hypertension guidelines now in the last couple of years?
《国际循环》：我们知道ESH/ESC和日本JSH刚刚更新了高血压治疗指南，现在，中国和美国也正在更新高血压指南。在您看来，为什么这些年来，这些组织都在不断地更新指南？
International Circulation: Cardiovascular risk assessment and its incorporation into treatment decisions is a clear strategy in hypertension management. What are your thoughts on this?
《国际循环》：对心血管危险因素进行评估，并且将其应用于高血压治疗方案的制定中已经作为一种例行的手段。您对此怎么看呢？
Prof Oparil: JNC7 did not do formal risk assessment at all. The National Heart， Lung and Blood Institute of the US National Institutes of Health has launched an effort at cardiovascular disease prevention and treatment guidelines which will include JNC8， our favorite， as well as ATP4， which deals with lipid management and another guideline which deals with obesity management which is a horrible thing in the United States， and then there are cross-cutting committees. One deals with risk assessment， one deals with lifestyle modifications and another deals with implementation， how you get all of these recommendations into practice. How we will integrate what the risk assessment group says with the JNC8 recommendations is yet to be determined.
Prof Oparil：JNC 7并没有做过正式的风险评估。美国健康研究中心的国家心肺血液研究所关于心血管疾病预防和治疗指导方面做出了一定的努力，这些将会收入JNC 8。我们更关注关于血脂以及肥胖处理的推荐，因为肥胖在美国是一个非常危险的因素。另外还有cross-cutting 委员会，一方面是关于危险因素评估，一方面关于生活方式调整，另外一方面是关于这些推荐方案的实施：如何将建议用于临床实践。JNC 8中我们如何整合危险因素评估仍然在决议中。
京公网安备 11010502033353号